Clinical trial · Interventional
Treatment Selection According to Skin Reaction to Cetuximab
Skin Reaction to Cetuximab as Criteria for Treatment Selection in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase 2 Study
NCT01472653CI-TRIAL-00005919unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The therapy of patients with locally advanced head and neck cancer will be adjusted to the grade of skin rush as recorded after the first two cycles of Cetuximab and Cisplatin, i.e. either with radioimmunotherapy (radiotherapy and Cetuximab) or radiochemotherapy (radiotherapy and Cisplatin.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- locoregional complete response rate
- timeFrame
- 12-14 weeks after therapy
- description
- The primary objective of the study is to determine radiologically the complete response rate 12-14 weeks after therapy.
Secondary outcomes (5)
- measure
- feasibility (toxicity profile) of the proposed regimen
- timeFrame
- participants will be followed for the duration of treatment (an expected average of 20 weeks)
- description
- number of patients with adverse events graded according to the National Cancer Institute CTC v3.0 (as measure of safety and tolerability)
- measure
- locoregional control
- timeFrame
- at 2 years after thapy
- description
- Locoregional control will be calculated from the first day of the therapy to the occurrence of the local and/or regional recurrence (whichever will occur first) or death from any cause other than distant metastasis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Squamous cell carcinoma, histologically proven (with HPV-status determined in patients with oropharyngeal primary) * Tumour site: oral cavity, oropharynx, hypopharynx or larynx. * Locally and/or regionally operable and inoperable tumors (UICC TNM stages III, IVa or IVb), without distant metastases (M0-stage) * Male or female ≥18 years of age * Expected survival \>6 months * WHO performance status 0-2 * Laboratory parameters: hemoglobin ≥100 g/L; leukocyte count \> 3.5x109/L, absolute neutrophil count ≥ 1.5x109/L; platelet count \> 100x109/L; total bilirubin \< 1.25x upper normal limit; transaminases (ALT, AST) \< 5x upper normal limit; creatinine clearance (ECC) ≥ 60 ml/minute; * Presence of at least one bidimensionally measurable index lesion * Effective contraception for both male and female subjects if risk of conception exists * Signed written informed consent Exclusion Criteria: * Other previous malignancy within 5 years, with exception of a history of a previously adequately treated basal cell carcinoma of the skin or pre- invasive carcinoma of the cervix * Chemotherapy ineligibility: unstable cardiopulmonary, renal and liver disease likely to compromise the safe delivery of I.V. infusion (chemotherapy); haematologic diseases; clinically evident hearing impairment; pre-existing motor or sensory neurotoxicity grade ≥ 2 according to the CTCAE v3.0; previous administration of Cetuximab or Cisplatin; * Active, uncontrolled infection * Medical or psychological condition which in the opinion of the investigator precludes the safe administration of the planned radiotherapy or systemic therapy * Known drug abuse or severe alcohol abuse * Pregnancy or breast feeding
References
Publications (0)
Data not yet available
No reference posted for this study.